Identifying Novel Biomarkers Ready for Evaluation in Low-Prevalence Populations for the Early Detection of Upper Gastrointestinal Cancers: A Systematic Review.

Natália CalanzaniPaige E DruceClaudia SnuddenKristi M MilleyRachel BoscottDawnya BehiyatSmiji SajiJaviera Martinez-GutierrezJasmeen OberoiGarth FunstonMike MessengerJon EmeryFiona M Walter

Published in: Advances in therapy (2020)

Most novel biomarkers for the early detection of upper GI cancers are still at an early stage of matureness. Further evidence is needed on biomarker performance in low-prevalence populations, in addition to implementation and health economic studies, before extensive adoption into clinical practice can be recommended.

Keyphrases

early stage
clinical practice
healthcare
risk factors
public health
primary care
mental health
genetic diversity
quality improvement
health information
squamous cell carcinoma
risk assessment
sentinel lymph node
radiation therapy
lymph node
human health